Literature DB >> 6948816

Determination of the antidepressant agent citalopram and metabolites in plasma by liquid chromatography with fluorescence detection.

E Oyehaug, E T Ostensen, B Salvesen.   

Abstract

A high-performance liquid chromatographic method is described for the determination of citalopram [1-(3-(dimethylaminopropyl)-1-(4-fluorophenyl)-5-phthalancarbonitrile] and its two main metabolites (the methylamino and amino derivatives). The compounds were extracted from alkaline plasma with diethyl ether. The combined ether layers were evaporated after addition of 50 microliter of 0.1 N HCl. The residual extracts were purified with diethyl ether and 20 microliter were injected into a Spherisorb ODS 5-micrometer column with acetonitrile--0.6% phosphate buffer pH 3 (55:45, v/v) as the mobile phase. Using a fluorescence detector the detection limits are 1 ng/ml of plasma for citalopram and the methylamino metabolite and 0.5 ng/ml for the amino metabolite.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6948816     DOI: 10.1016/s0378-4347(00)80362-x

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

1.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

2.  Antidepressant response to chronic citalopram treatment in eight inbred mouse strains.

Authors:  Jianwei Jiao; Angela M Nitzke; Demetrios G Doukas; Mariel P Seiglie; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

3.  Serum BDNF levels before treatment predict SSRI response in depression.

Authors:  Owen M Wolkowitz; Jessica Wolf; Wendy Shelly; Rebecca Rosser; Heather M Burke; George K Lerner; Victor I Reus; J Craig Nelson; Elissa S Epel; Synthia H Mellon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-07-03       Impact factor: 5.067

4.  Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.

Authors:  Helen B Simpson; Edna B Foa; Michael G Wheaton; Thea Gallagher; Marina Gershkovich; Andrew B Schmidt; Jonathan D Huppert; Raphael B Campeas; Patricia A Imms; Shawn P Cahill; Christina DiChiara; Steven D Tsao; Anthony C Puliafico; Daniel Chazin; Anu Asnaani; Kelly Moore; Jeremy Tyler; Shari A Steinman; Arturo Sanchez-LaCay; Sandy Capaldi; Ivar Snorrason; Elizabeth Turk-Karan; Donna Vermes; Eyal Kalanthroff; Anthony Pinto; Chang-Gyu Hahn; Bin Xu; Page E Van Meter; Martha Katechis; Jennifer Scodes; Yuanjia Wang
Journal:  Behav Res Ther       Date:  2021-05-29

5.  Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.

Authors:  Gwenn S Smith; Hiroto Kuwabara; Neda F Gould; Najilla Nassery; Alena Savonenko; Jin Hui Joo; Kristin L Bigos; Michael Kraut; James Brasic; Daniel P Holt; Andrew W Hall; William B Mathews; Robert F Dannals; Ayon Nandi; Clifford I Workman
Journal:  Neuropharmacology       Date:  2021-01-12       Impact factor: 5.273

6.  Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial.

Authors:  Yvette I Sheline; B Joy Snider; Joanne C Beer; Darsol Seok; Anne M Fagan; Raymond F Suckow; Jin-Moo Lee; Teresa Waligorska; Magdalena Korecka; Irem Aselcioglu; John C Morris; Leslie M Shaw; John R Cirrito
Journal:  Neurology       Date:  2020-09-10       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.